Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study

Induction of remission is easily achieved with dietary treatment in dogs diagnosed with Food Responsive Chronic Diarrhea (FRD). Administration of prebiotics and glycosaminoglycans (GAGs) may improve epithelial cell integrity and therefore be useful as adjunct treatment. This study evaluated whether...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Barbara Glanemann, Yeon-Jung Seo, Simon L. Priestnall, Oliver A. Garden, Logan Kilburn, Mariana Rossoni-Serao, Sergi Segarra, Jonathan P. Mochel, Karin Allenspach
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/faf7a60e6ef440168e2d49c962b78e8d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:faf7a60e6ef440168e2d49c962b78e8d
record_format dspace
spelling oai:doaj.org-article:faf7a60e6ef440168e2d49c962b78e8d2021-11-04T06:07:19ZClinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study1932-6203https://doaj.org/article/faf7a60e6ef440168e2d49c962b78e8d2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530283/?tool=EBIhttps://doaj.org/toc/1932-6203Induction of remission is easily achieved with dietary treatment in dogs diagnosed with Food Responsive Chronic Diarrhea (FRD). Administration of prebiotics and glycosaminoglycans (GAGs) may improve epithelial cell integrity and therefore be useful as adjunct treatment. This study evaluated whether the relapse rate of FRD dogs that are switched back to a normal diet can be influenced using supplemental treatment with prebiotics and GAGs. A randomized, controlled clinical trial (RCCT) was performed in dogs diagnosed with FRD. Dogs were diagnosed based on clinical exclusion diagnosis, endoscopic biopsies showing predominantly lymphoplasmacytic infiltration, and response to dietary treatment. Dogs were randomized to be fed a combination of prebiotics and GAGs (group 1) or placebo (group 2) in addition to a hydrolyzed diet. At week 10, a second endoscopy was performed and dogs were switched back to normal diet. Relapse rate was monitored every 2 weeks after that until week 18. Statistical analysis was performed for each outcome (Canine Chronic Enteropathy Clinical Activity Index (CCECAI), clinicopathological data, endoscopic scoring, mWSAVA histological scoring index (mWSAVA), and number of relapses following switch to normal diet) using a linear mixed effects model for group comparison. Time, group, and their interactions were included as a fixed effect, whereas each dog was treated as a random effect. Of the 35 dogs enrolled into the clinical trial, 10 in each group reached the point of second endoscopy. A total of 13 dogs (n = 8 in group 1 and n = 5 in group 2) reached the trial endpoint of 18 weeks. After switching back to normal diet, none of the dogs in either group relapsed. No significant differences were found over time or between groups for CCECAI, endoscopy scoring and histological scoring. Although there was a clinical worsening in the placebo group after switching back to the original diet, this was not statistically significant (CCECAI p = 0.58). Post-hoc power calculation revealed that 63 dogs per group would have been needed to detect statistically significant differences in CIBDAI between treatment groups. Standard dietary treatment induced rapid clinical response in all cases, however, additional supplementation with prebiotics and GAGs did not significantly improve clinical outcome within 4 months after switching back to normal diet. Since there are very few RCCT published in CE in dogs, this pilot study provides important power analyses for planning of further studies.Barbara GlanemannYeon-Jung SeoSimon L. PriestnallOliver A. GardenLogan KilburnMariana Rossoni-SeraoSergi SegarraJonathan P. MochelKarin AllenspachPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Barbara Glanemann
Yeon-Jung Seo
Simon L. Priestnall
Oliver A. Garden
Logan Kilburn
Mariana Rossoni-Serao
Sergi Segarra
Jonathan P. Mochel
Karin Allenspach
Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
description Induction of remission is easily achieved with dietary treatment in dogs diagnosed with Food Responsive Chronic Diarrhea (FRD). Administration of prebiotics and glycosaminoglycans (GAGs) may improve epithelial cell integrity and therefore be useful as adjunct treatment. This study evaluated whether the relapse rate of FRD dogs that are switched back to a normal diet can be influenced using supplemental treatment with prebiotics and GAGs. A randomized, controlled clinical trial (RCCT) was performed in dogs diagnosed with FRD. Dogs were diagnosed based on clinical exclusion diagnosis, endoscopic biopsies showing predominantly lymphoplasmacytic infiltration, and response to dietary treatment. Dogs were randomized to be fed a combination of prebiotics and GAGs (group 1) or placebo (group 2) in addition to a hydrolyzed diet. At week 10, a second endoscopy was performed and dogs were switched back to normal diet. Relapse rate was monitored every 2 weeks after that until week 18. Statistical analysis was performed for each outcome (Canine Chronic Enteropathy Clinical Activity Index (CCECAI), clinicopathological data, endoscopic scoring, mWSAVA histological scoring index (mWSAVA), and number of relapses following switch to normal diet) using a linear mixed effects model for group comparison. Time, group, and their interactions were included as a fixed effect, whereas each dog was treated as a random effect. Of the 35 dogs enrolled into the clinical trial, 10 in each group reached the point of second endoscopy. A total of 13 dogs (n = 8 in group 1 and n = 5 in group 2) reached the trial endpoint of 18 weeks. After switching back to normal diet, none of the dogs in either group relapsed. No significant differences were found over time or between groups for CCECAI, endoscopy scoring and histological scoring. Although there was a clinical worsening in the placebo group after switching back to the original diet, this was not statistically significant (CCECAI p = 0.58). Post-hoc power calculation revealed that 63 dogs per group would have been needed to detect statistically significant differences in CIBDAI between treatment groups. Standard dietary treatment induced rapid clinical response in all cases, however, additional supplementation with prebiotics and GAGs did not significantly improve clinical outcome within 4 months after switching back to normal diet. Since there are very few RCCT published in CE in dogs, this pilot study provides important power analyses for planning of further studies.
format article
author Barbara Glanemann
Yeon-Jung Seo
Simon L. Priestnall
Oliver A. Garden
Logan Kilburn
Mariana Rossoni-Serao
Sergi Segarra
Jonathan P. Mochel
Karin Allenspach
author_facet Barbara Glanemann
Yeon-Jung Seo
Simon L. Priestnall
Oliver A. Garden
Logan Kilburn
Mariana Rossoni-Serao
Sergi Segarra
Jonathan P. Mochel
Karin Allenspach
author_sort Barbara Glanemann
title Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
title_short Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
title_full Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
title_fullStr Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
title_full_unstemmed Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
title_sort clinical efficacy of prebiotics and glycosaminoglycans versus placebo in dogs with food responsive enteropathy receiving a hydrolyzed diet: a pilot study
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/faf7a60e6ef440168e2d49c962b78e8d
work_keys_str_mv AT barbaraglanemann clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT yeonjungseo clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT simonlpriestnall clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT oliveragarden clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT logankilburn clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT marianarossoniserao clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT sergisegarra clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT jonathanpmochel clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
AT karinallenspach clinicalefficacyofprebioticsandglycosaminoglycansversusplaceboindogswithfoodresponsiveenteropathyreceivingahydrolyzeddietapilotstudy
_version_ 1718445188772265984